Daratumumab (with Recombinant Human Hyaluronidase)injection, CAS No.: 945721-28-8

A: Our Daratumumab formulation incorporates Recombinant Human Hyaluronidase as a cutting-edge permeability enhancer, transforming the treatment from a 3–7 hour intravenous (IV) infusion into a rapid 3–5 minute subcutaneous (SC) injection. This innovation works by temporarily and reversibly breaking down hyaluronan in the extracellular matrix, allowing for the comfortable delivery of large-volume biologics while significantly reducing the risk of infusion-related reactions (IRRs). For pharmaceutical distributors and healthcare providers, this subcutaneous delivery system not only maximizes clinic throughput and reduces medical overhead but also drastically improves patient compliance and quality of life, positioning your portfolio at the forefront of the global trend toward rapid-care oncology solutions.